Loomis, Sayles & Company
NBIX icon

Loomis, Sayles & Company’s Neurocrine Biosciences NBIX Stock Holding History

Loomis, Sayles & Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.8M Sell
165,735
-3,485
-2% -$462K 0.03% 225
2025
Q4 		$24M Buy
169,220
+8,404
+5% +$1.22M 0.03% 211
2025
Q3 		$22.6M Buy
160,816
+20,332
+14% +$2.75M 0.03% 222
2025
Q2 		$17.7M Buy
+140,484
New +$16.1M 0.02% 261
2024
Q4 		– Sell
-150,337
Closed -$17.3M – 769
2024
Q3 		$17.3M Sell
150,337
-9,933
-6% -$1.36M 0.02% 281
2024
Q2 		$22.1M Sell
160,270
-94,663
-37% -$13M 0.03% 245
2024
Q1 		$35.2M Sell
254,933
-936
-0.4% -$128K 0.05% 174
2023
Q4 		$33.7M Sell
255,869
-1,057
-0.4% -$122K 0.05% 177
2023
Q3 		$28.9M Buy
256,926
+49,787
+24% +$5.24M 0.05% 193
2023
Q2 		$19.5M Buy
207,139
+44,136
+27% +$4.31M 0.03% 254
2023
Q1 		$16.5M Buy
+163,003
New +$17M 0.03% 261
2022
Q4 		– Sell
-1,910
Closed -$203K – 947
2022
Q3 		$203K Sell
1,910
-142
-7% -$14.4K ﹤0.01% 472
2022
Q2 		$200K Buy
2,052
+19
+0.9% +$1.75K ﹤0.01% 504
2022
Q1 		$191K Buy
+2,033
New +$172K ﹤0.01% 554
2021
Q4 		– Sell
-270,355
Closed -$25.9M – 859
2021
Q3 		$25.9M Buy
270,355
+7,531
+3% +$711K 0.03% 269
2021
Q2 		$25.6M Buy
262,824
+10,327
+4% +$990K 0.03% 268
2021
Q1 		$24.6M Buy
252,497
+377
+0.1% +$39.5K 0.03% 261
2020
Q4 		$24.2M Buy
252,120
+48,721
+24% +$4.71M 0.03% 237
2020
Q3 		$19.6M Buy
203,399
+17,892
+10% +$2.07M 0.03% 236
2020
Q2 		$22.6M Buy
185,507
+14,362
+8% +$1.59M 0.04% 200
2020
Q1 		$14.8M Sell
171,145
-2,772
-2% -$271K 0.03% 227
2019
Q4 		$18.7M Sell
173,917
-12,541
-7% -$1.31M 0.03% 227
2019
Q3 		$16.8M Buy
186,458
+68,786
+58% +$6.43M 0.03% 239
2019
Q2 		$9.94M Sell
117,672
-7,085
-6% -$582K 0.02% 344
2019
Q1 		$11M Buy
124,757
+22,744
+22% +$1.9M 0.02% 330
2018
Q4 		$7.28M Buy
102,013
+1,121
+1% +$107K 0.02% 370
2018
Q3 		$12.4M Sell
100,892
-8,047
-7% -$913K 0.02% 325
2018
Q2 		$10.7M Sell
108,939
-3,824
-3% -$342K 0.02% 402
2018
Q1 		$9.35M Sell
112,763
-2,016
-2% -$170K 0.02% 441
2017
Q4 		$8.91M Buy
114,779
+9,330
+9% +$636K 0.02% 457
2017
Q3 		$6.46M Sell
105,449
-2,735
-3% -$144K 0.01% 491
2017
Q2 		$4.98M Buy
108,184
+22,980
+27% +$1.11M 0.01% 513
2017
Q1 		$3.69M Buy
85,204
+14,396
+20% +$617K 0.01% 538
2016
Q4 		$2.74M Sell
70,808
-1,174
-2% -$53.1K 0.01% 569
2016
Q3 		$3.65M Buy
71,982
+71,819
+44,061% +$3.58M 0.01% 545
2016
Q2 		$7K Buy
163
+53
+48% +$2.44K ﹤0.01% 800
2016
Q1 		$4K Sell
110
-337,604
-100% -$13.4M ﹤0.01% 956
2015
Q4 		$19.1M Buy
337,714
+45,023
+15% +$2.29M 0.05% 302
2015
Q3 		$11.6M Buy
292,691
+3,891
+1% +$188K 0.03% 408
2015
Q2 		$13.8M Buy
288,800
+38,837
+16% +$1.65M 0.04% 422
2015
Q1 		$9.93M Sell
249,963
-225,877
-47% -$8.08M 0.03% 493
2014
Q4 		$10.6M Sell
475,840
-558,519
-54% -$10.6M 0.03% 493
2014
Q3 		$16.2M Sell
1,034,359
-23,874
-2% -$357K 0.05% 397
2014
Q2 		$15.7M Buy
1,058,233
+188,869
+22% +$2.67M 0.04% 431
2014
Q1 		$14M Buy
+869,364
New +$14.9M 0.04% 447
2013
Q3 		– Sell
-1,120,333
Closed -$15K – 759
2013
Q2 		$15K Buy
+1,120,333
New +$13.8M 0.05% 385

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's NBIX Position: Q1 2026 in Review

Loomis, Sayles & Company reduced its Neurocrine Biosciences (NBIX) stake by 2.1% in Q1 2026, selling an estimated $462K and leaving 165,735 shares worth $21.8M. The position accounts for 0.03% of the portfolio, ranked #225.

Loomis, Sayles & Company first reported a position in NBIX in Q2 2013 and has held it in 46 quarters since. The position peaked at $35.2M in Q1 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Loomis, Sayles & Company held 165,735 shares of Neurocrine Biosciences worth $21.8M as of Q1 2026.
  • Loomis, Sayles & Company sold 3,485 Neurocrine Biosciences shares in Q1 2026, an estimated $462K.
  • Neurocrine Biosciences made up 0.03% of Loomis, Sayles & Company's portfolio in Q1 2026, its #225 holding.
  • Loomis, Sayles & Company first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 46 quarters since.
  • Loomis, Sayles & Company's Neurocrine Biosciences position peaked at $35.2M in Q1 2024.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.